Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
Newswise — In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with…
Read more Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer